Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.28B P/E 16.36 EPS this Y 24.60% Ern Qtrly Grth 7.30%
Income 1.07B Forward P/E 11.66 EPS next Y 9.70% 50D Avg Chg 6.00%
Sales 2.62B PEG 0.82 EPS past 5Y 18.55% 200D Avg Chg -
Dividend N/A Price/Book 2.09 EPS next 5Y 17.60% 52W High Chg -15.00%
Recommedations 2.20 Quick Ratio 3.97 Shares Outstanding 44.49M 52W Low Chg 19.00%
Insider Own 1.86% ROA 11.79% Shares Float 40.80M Beta 0.57
Inst Own 105.77% ROE 19.25% Shares Shorted/Prior 4.08M/4.14M Price 240.85
Gross Margin 88.85% Profit Margin 40.87% Avg. Volume 368,045 Target Price 367.52
Oper. Margin 44.75% Earnings Date Oct 30 Volume 941,550 Change 0.30%
About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation News
11/29/24 Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
11/28/24 The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314%
11/21/24 Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
11/20/24 Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
11/05/24 United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
11/05/24 United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?
11/04/24 United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?
11/01/24 United Therapeutics Q3 Earnings & Sales Beat Estimates
10/31/24 United Therapeutics Corp (UTHR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
10/31/24 Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight
10/30/24 Q3 2024 United Therapeutics Corp Earnings Call
10/30/24 Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings
10/30/24 United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
10/30/24 United Therapeutics: Q3 Earnings Snapshot
10/30/24 United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
10/29/24 Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics
10/24/24 Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
10/23/24 United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
10/23/24 United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
10/18/24 Profitable Biotech In Buy Zone As Earnings Approach
UTHR Chatroom

User Image trondisc Posted - 2 hours ago

Once #ComatoseCastagnant is given the drop kick after a $MNKD buyout/hostile takeover post PED approval, maybe we’ll finally have our 10+ PPS euphoria ala $NVCR or $TNDM 2018-2021 meteoric rise. Infinite thanks to $UTHR leveraging/protecting/salvaging Technosphere’s unmatched ultra-rapid acting peak activation time. #InTechnosphereWeTrust #MathIsNotHard #ChiefExcuseOfficer #MikeHas2Go #TrueLongs #PreReverseSplit #GiveHimTheGuillotine #DecemberMassacre #EarnedTheRight2PissAndMoan #RestAndNeverGrow #Paltry127kProfit #RetirementUnfux0red #ReadySetInhale #Access4Patients #MediocreMike #NewLeadershipNow #BotchedUAE #MoronMike #MidTierMike #MalignantMike #MalaiseMike #MisguidedMike #MinorLeagueMike #MismanagementMike #PfefferSucks #Bourla4BOD #Hooper4CEO #Bradway4BOD #GeoffMartha4BOD #Rothblatt4BOD #Joergensen4BOD #SayerTheSavior4BOD #SendHelpMyCEOIsMeh #GreedyCEgO #CEOsabotage #CEOsuffocation

User Image trondisc Posted - 11/29/24

Grueling 9 years since investing into Al Mann’s $MNKD vision. 2015-2019 thought I would never recover my 70k again. 2020 showed a blip on the radar. 2021 actual pulse. 2022 volatile backpedaling & rubberbanding. 2023 signs of flat stabilization confirmed. 2024 the ascent from $UTHR Tyvaso. #InTechnosphereWeTrust #ComatoseCastagnant #MathIsNotHard #ChiefExcuseOfficer #MikeHas2Go #TrueLongs #PreReverseSplit #GiveHimTheGuillotine #DecemberMassacre #EarnedTheRight2PissAndMoan #RestAndNeverGrow #Paltry133kProfit #RetirementUnfux0red #ReadySetInhale #Access4Patients #MediocreMike #NewLeadershipNow #BotchedUAE #MoronMike #MidTierMike #MalignantMike #MalaiseMike #MisguidedMike #MinorLeagueMike #MismanagementMike #PfefferSucks #Bourla4BOD #Hooper4CEO #Bradway4BOD #GeoffMartha4BOD #Rothblatt4BOD #Joergensen4BOD #SayerTheSavior4BOD #SendHelpMyCEOIsMeh #GreedyCEgO #CEOsabotage #CEOsuffocation

User Image Hard2beLong Posted - 11/26/24

$MNKD what happened to pstx with Roche will happen here with $UTHR

User Image grampslol Posted - 11/25/24

$MNKD Won't President Trump really own da libs and open a big 'ol can of whoop ass on Woke D.E.I. and Trans co.'s like MNKD $uthr

User Image NVDAMillionaire Posted - 11/25/24

$UTHR United Therapeutics Corporation (UTHR): A Powerhouse in Pulmonary Hypertension and Beyond https://beyondspx.com/article/united-therapeutics-corporation-uthr-a-powerhouse-in-pulmonary-hypertension-and-beyond

User Image UncleStock Posted - 11/23/24

$AVT $EXEL $ZM $UTHR suggested for $RUI US Russell 1000 Index - value screen: https://zpr.io/tey68

User Image clan Posted - 11/23/24

$LQDA Liquidati💩 still does not have an approved trademark for Yutrepi💩 #thievesandliars #fraudsters #moredilutioncoming $UTHR = TD (total domination)

User Image UncleStock Posted - 11/22/24

$EXEL $UTHR $CORT $NBIX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image The_Hungry_Wolf Posted - 11/21/24

$VRPX 100% up in after hours Next stop 150% LET'S FUCKING GOOOOOOO $SNDL $UTHR $KIRK

User Image HayleyMason__ Posted - 11/19/24

🚨 STOCK ALERT: MYNZ 🚨 🔥 Frankie Muniz is ALL IN—Malcolm in the Middle star & NASCAR #33 driver is now repping MYNZ! 🔎 Petra (ex-Obama advisor) dropped hints about a major U.S. lab partnership—this could be game-changing. 📈 6 news hits in 3 weeks = strong momentum. Something BIG is building here. 🌍 Already solid in the EU market, expanding with insurance-covered tests—this isn’t just hype, it’s execution. 💡 Their test has 88% accuracy, crushing competitors: EXAS (42%) & GH (20%)—clear leader in diagnostics. 💰 $1.5M private placement secured = cash on hand to scale up. 🚀 CEO teasing big plans ahead—keep an eye on this leadership. 📊 New offering deal + TMO partnership = validation and growth catalysts. ⚡ MYNZ is ticking all the boxes for a breakout! Don’t let this one fly under your radar! 💥 $BIIB $BGNE $UTHR

User Image cubie Posted - 11/18/24

@jenbunn @judgeyoung2 @Alvi722 @lowfloatscambuster @EBE_Day @Ollip @ribbey @TraderRapp @tonyctl @lukenight $biib $BMRN 52 week lows today, $UTHR $tmo $regn more pharma and bio related stonks that pullbacked lot recently

User Image clan Posted - 11/18/24

$MNKD OFEV DPI? Or other p'ship coming? TMD - Total Market Domination! The fix is in. Just breathe. $BMY $SDZXF $UTHR

User Image Omega_Proxy Posted - 11/16/24

$UTHR Here comes the recession....

User Image grampslol Posted - 11/14/24

$UTHR sinking AH $LQDA leak ? $MNKD

User Image UncleStock Posted - 11/14/24

$AVT $EXEL $ZM $UTHR suggested for $RUI US Russell 1000 Index - value screen: https://zpr.io/tey68

User Image TheTradingAgent Posted - 11/09/24

$XBI daily, breaking out? Worth watching the $104's. $IBB $INCY $UTHR The Best Market Review for November 8th, 2024 https://youtu.be/FjDvZADXjis Turn Profits into Properties and Passive Income http://thetradingagent.com Please share, like, or leave a comment! Let me know how I can help!

User Image nomalarkey Posted - 11/08/24

$MNKD is no $UTHR. I've said it before and I'll say it again. Martine has bigger balls than Mike and that's saying something.

User Image MrMulally Posted - 11/08/24

$UTHR another ATH . Love it. 🥰 last add was at $352 right before ER. $MNKD will have ATH next week. Might even close green today.

User Image neuroinvestor3 Posted - 11/08/24

$CLNN $UTHR is on a tear and owns 2% of Clene. I'll say it again, give them licensing and distribution deal in exchange for CNM-Au8 phase 3 trial costs for ALS, PD and MS. Would have little impact on UTHR balance sheet and huge upside potential for everyone....

User Image Ocean1162 Posted - 11/08/24

$MNKD $UTHR still reaching new highs daily, just like we did until now, so remember to stay strong and not to sell. It’s not even the time to secure profits. We are still on the way up.

User Image UncleStock Posted - 11/07/24

$EXEL $ZM $UTHR $THC suggested for $RUI US Russell 1000 Index - value screen: https://zpr.io/tey68

User Image clan Posted - 11/07/24

@TC00 $MNKD $UTHR $SNY

User Image amstelytle Posted - 11/07/24

$UTHR $MNKD What does Oppenheimer know?

User Image Golf365 Posted - 11/06/24

$MNKD They have $UTHR @417 AH ??

User Image UncleStock Posted - 11/06/24

$EXEL $UTHR $CORT $NBIX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image neofeudal Posted - 11/06/24

$LNTH Lantheus is one upgrade away from exploding upwards to compensate for today's absurd 20% drop on earnings triumph with positive guidance. And we'll get that upgrade, because the numbers bear it out in spades. $PFE $MRNA $UTHR

User Image Kool_Aid_Mann Posted - 11/06/24

$MNKD What is the earnings estimate for the Q? I see .04, .05? Obviously it will be much, much higher based on $UTHR, but what is the expected consensus?

User Image Kool_Aid_Mann Posted - 11/06/24

$MNKD getting left behind, while $UTHR and $XBI soar away to new highs. 7.50 call options and weak leadership, I guess we will just have to wait until the gap up over $8 after earnings. Remember, we are funded by $UTHR, if they're breaking revenue records, so are we.

User Image gravityattracts Posted - 11/06/24

$UTHR Market cap approaching 18B - incredible. Can only be great news for $MNKD so I’m super happy to own both. Great time to invest in biotech.

User Image neofeudal Posted - 11/06/24

$LNTH Lantheus is clearly the best deal on the market today. Smashed its earnings, price manipulated down 25%. $PFE $MRNA $UTHR

Analyst Ratings
Jefferies Buy Sep 23, 24
Oppenheimer Outperform Aug 28, 24
Wells Fargo Overweight Aug 20, 24
HC Wainwright & Co. Buy Aug 1, 24
B of A Securities Underperform Aug 1, 24
HC Wainwright & Co. Buy Jul 25, 24
TD Cowen Buy Jul 11, 24
Morgan Stanley Equal-Weight Jul 11, 24
UBS Buy Jul 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Jan 18 Sell 219.78 6,000 1,318,680 36,599 01/18/24
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Jan 18 Option 117.76 6,000 706,560 42,599 01/18/24
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Dec 21 Sell 227 6,000 1,362,000 36,599 12/26/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Dec 21 Option 117.76 6,000 706,560 42,599 12/26/23
CAUSEY CHRISTOPHER Director Director Dec 12 Sell 249.68 3,000 749,040 4,585 12/13/23
CAUSEY CHRISTOPHER Director Director Dec 12 Option 175.43 3,000 526,290 7,585 12/13/23
PATUSKY CHRISTOPHER Director Director Nov 07 Option 88.03 2,000 176,060 3,684 11/08/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Oct 19 Sell 226.59 6,000 1,359,540 36,599 10/20/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Oct 19 Option 117.76 6,000 706,560 42,599 10/20/23
Mesa Nilda Director Director Sep 13 Sell 222.3609 383 85,164 6,303 09/15/23
Mesa Nilda Director Director May 05 Sell 214.805 374 80,337 5,806 05/08/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Apr 20 Option 120.26 6,000 721,560 42,599 04/20/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Apr 20 Sell 224.42 6,000 1,346,520 36,599 04/20/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Mar 22 Sell 216.4 16,000 3,462,400 130 03/24/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Mar 22 Option 113.08 16,000 1,809,280 8,130 03/24/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Mar 16 Sell 214.3 6,000 1,285,800 36,599 03/17/23
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Mar 16 Option 120.26 6,000 721,560 42,599 03/17/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Mar 08 Sell 226.07 16,000 3,617,120 130 03/10/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Mar 08 Option 113.08 16,000 1,809,280 8,130 03/10/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Jan 26 Sell 262.28 16,000 4,196,480 130 01/30/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Jan 26 Option 113.08 16,000 1,809,280 8,130 01/30/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Jan 20 Sell 260.31 16,000 4,164,960 130 01/24/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Jan 20 Option 113.08 16,000 1,809,280 8,130 01/24/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Jan 11 Sell 261.91 16,000 4,190,560 130 01/13/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Jan 11 Option 113.08 16,000 1,809,280 8,130 01/13/23
CAUSEY CHRISTOPHER Director Director Jan 03 Sell 276.26 1,000 276,260 2,835 01/03/23
CAUSEY CHRISTOPHER Director Director Jan 03 Option 175.43 1,000 175,430 3,835 01/03/23
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Dec 27 Sell 275.4 16,000 4,406,400 130 12/29/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Dec 27 Option 113.08 16,000 1,809,280 8,130 12/29/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Dec 20 Option 113.08 16,000 1,809,280 8,130 12/22/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Dec 20 Sell 273.52 16,000 4,376,320 130 12/22/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Nov 25 Option 113.08 16,000 1,809,280 8,130 11/29/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Nov 25 Sell 268.6 16,000 4,297,600 130 11/29/22
Thompson Tommy G Director Director Nov 23 Option 63.9 5,000 319,500 12,600 11/25/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Nov 22 Option 113.08 16,000 1,809,280 8,130 11/25/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO Nov 22 Sell 268.78 16,000 4,300,480 130 11/25/22
Olian Judy D. Director Director Nov 07 Sell 265.09 600 159,054 8,665 11/08/22
DWEK RAYMOND Director Director Sep 09 Option 63.9 3,000 191,700 3,000 09/12/22
CAUSEY CHRISTOPHER Director Director Aug 23 Option 175.43 3,500 614,005 6,335 08/25/22
CAUSEY CHRISTOPHER Director Director Aug 23 Sell 224.96 3,500 787,360 2,835 08/25/22
PATUSKY CHRISTOPHER Director Director Aug 17 Option 75.97 3,000 227,910 3,180 08/18/22
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Aug 04 Option 111 4,552 505,272 40,949 08/04/22
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Aug 04 Sell 225.81 4,552 1,027,887 36,397 08/04/22
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Jul 21 Option 111 6,000 666,000 42,397 07/22/22
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Jul 21 Sell 226.12 6,000 1,356,720 36,397 07/22/22
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Jul 07 Option 111 6,000 666,000 42,397 07/08/22
MAHON PAUL A EVP & GENERAL COUNSE.. EVP & GENERAL COUNSEL Jul 07 Sell 242.21 6,000 1,453,260 36,397 07/08/22
DWEK RAYMOND Director Director May 26 Option 63.9 5,000 319,500 7,000 05/26/22
Thompson Tommy G Director Director May 26 Option 48.11 2,200 105,842 8,720 05/26/22
ROTHBLATT MARTINE A CHAIRPERSON & CEO CHAIRPERSON & CEO May 25 Option 53.42 6,000 320,520 3,130 05/26/22